How Next-Generation DNA Panels Confirm Inherited Renal Phosphate Wasting

Inherited renal phosphate wasting refers to a group of genetic disorders in which the kidneys fail to reabsorb enough phosphate back into the bloodstream. Phosphate is vital for bone strength, muscle function and energy metabolism. When phosphate levels remain chronically low, patients can experience bone pain, weakness, dental problems and growth issues in children.

Advances in genetic testing—especially next-generation DNA panels—now allow doctors to identify specific gene mutations responsible for phosphate wasting. Two of the most common culprits are mutations in the PHEX gene (X-linked hypophosphatemia) and in the DMP1 gene (autosomal recessive hypophosphatemic rickets type 1). Confirming these mutations can:

• Clarify the exact cause of phosphate wasting
• Guide treatment choices, such as phosphate supplements versus newer biologic therapies
• Inform prognosis and help with genetic counseling for family members

Below is a concise overview of how next-generation sequencing panels work, why testing for PHEX and DMP1 mutations matters, and what to expect when you or your child undergoes testing.

Understanding Renal Phosphate Wasting

• Phosphate is filtered by the kidneys and reabsorbed in the proximal tubules.
• Inherited defects disrupt this reabsorption, leading to excessive phosphate loss.
• Chronic hypophosphatemia (low blood phosphate) can result in softened bones (rickets in children, osteomalacia in adults), muscle weakness and dental issues.

The two most common inherited forms are:

• X-linked hypophosphatemia (XLH) – caused by PHEX gene mutations
• Autosomal recessive hypophosphatemic rickets type 1 (ARHR1) – caused by DMP1 gene mutations

Role of PHEX and DMP1 in Phosphate Homeostasis

• PHEX gene: Produces an enzyme that regulates levels of fibroblast growth factor-23 (FGF23). When PHEX is mutated, FGF23 levels rise, causing reduced phosphate reabsorption.
• DMP1 gene: Controls bone mineralization and also influences FGF23 production. Mutations elevate FGF23, mimicking the PHEX pathway’s impact on kidneys.

Elevated FGF23 is the final common pathway in many phosphate-wasting disorders. It signals the kidneys to excrete more phosphate and suppresses vitamin D activation, further lowering phosphate absorption from the gut.

Why Genetic Testing Matters

1. Diagnostic certainty
   – Clinical symptoms (bone pain, growth delays, dental abscesses) and lab findings (low serum phosphate, elevated alkaline phosphatase) can suggest renal phosphate wasting but don’t pinpoint the underlying gene.

2. Personalized therapy
   – Identifying a PHEX mutation may steer treatment toward burosumab (an anti-FGF23 antibody), whereas other conditions might respond better to conventional phosphate and active vitamin D supplements.

3. Family planning and counseling
   – X-linked inheritance (PHEX) carries a 50% risk to male children of an affected mother, while DMP1 follows autosomal recessive patterns, with a 25% recurrence risk if both parents are carriers.

4. Prognosis and monitoring
   – Knowledge of the specific mutation helps anticipate potential complications—such as dental abscesses in XLH—and plan early interventions.

Next-Generation DNA Panels: What They Are and How They Work

Next-generation sequencing (NGS) panels allow simultaneous analysis of dozens—or even hundreds—of genes known to cause similar symptoms. In the context of inherited phosphate wasting, a renal or metabolic bone disease panel typically includes PHEX, DMP1 and other related genes (e.g., FGF23, ENPP1).

Key advantages:

• High throughput: Millions of DNA fragments are sequenced at once, reducing time and cost.
• Broader coverage: Detects single-nucleotide changes, small insertions/deletions and some copy-number variations.
• Scalability: Panels can be updated as new phosphate-wasting genes are discovered.

Testing Process

1. Sample collection
   • A blood draw or saliva sample is sent to a certified genetics laboratory.

2. DNA extraction and sequencing
   • DNA is isolated and fragmented.
   • Fragments are amplified and sequenced in parallel.

3. Bioinformatic analysis
   • Raw sequence data are aligned to the reference human genome.
   • Variants are identified and classified (pathogenic, likely pathogenic, uncertain significance, etc.).

4. Clinical interpretation
   • A geneticist or molecular pathologist reviews the findings in the context of clinical presentation and family history.
   • A report is issued, often including recommendations for family testing or referral to a genetic counselor.

Focus on Genetic Testing for PHEX and DMP1 Mutations

• PHEX testing
– Pathogenic PHEX mutations confirm X-linked hypophosphatemia.
– Examples include nonsense mutations, splice-site changes and large deletions.
– A positive result typically explains the phenotype if labs show low phosphate and elevated FGF23.

• DMP1 testing
– Pathogenic DMP1 mutations indicate autosomal recessive hypophosphatemic rickets type 1.
– Both parents must carry one copy of the mutated gene.
– Homozygous or compound heterozygous mutations confirm diagnosis.

Variant interpretation follows guidelines from the American College of Medical Genetics and Genomics (ACMG). Variants of uncertain significance (VUS) may require further testing—such as testing other family members—to clarify their role.

Clinical Application and Next Steps

Once a pathogenic mutation in PHEX or DMP1 is confirmed:

• Treatment planning
– Burosumab may be approved for PHEX-related disease.
– Conventional therapy includes oral phosphate supplements and calcitriol (active vitamin D).

• Monitoring and follow-up
– Regular assessments of serum phosphate, bone density scans and growth parameters in children.
– Dental evaluations to prevent abscesses and enamel defects.

• Family screening
– Offer targeted testing to at-risk relatives (siblings, children).
– Provide genetic counseling to discuss inheritance patterns and reproductive options.

• Research and clinical trials
– Genetic confirmation can grant access to trials of novel therapies targeting FGF23 or bone mineralization pathways.

When to Consider Testing

You or your child might consider genetic testing if you have:

• Persistent low blood phosphate despite standard interventions
• Signs of rickets or osteomalacia without a clear nutritional cause
• A family history of hypophosphatemia, bone pain or early tooth loss

If you’re unsure whether your symptoms fit this profile, you may wish to consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker before scheduling a specialist consultation.

Questions to Discuss with Your Doctor

• Do I or my child meet criteria for genetic testing?
• Which genes are included in the next-generation panel?
• How long will it take to get results, and what do different results mean?
• What treatment options should follow a positive test for PHEX or DMP1?
• Should my family members be tested, too?

Always speak to a doctor about any serious symptoms—such as severe bone pain, inability to walk or sudden dental abscesses—that could indicate complications of phosphate wasting or other health conditions.

---

By confirming specific mutations through next-generation DNA panels, patients gain clarity on diagnosis, treatment and family planning. Genetic testing for PHEX and DMP1 mutations transforms uncertainty into actionable information, empowering you and your healthcare team to tailor care for optimal bone health and overall well-being.